Kornimate/medical-research-clean huggingface dataset:
influence of ffr on the clinical outcome after percutaneous coronary intervention

Conditions: Coronary Disease

Summary: fractional flow reserve (ffr) is a physiologic index for the determination of ischemia-causing coronary stenosis as well as drug eluting stent (des) optimization, even multiple anatomic imaging parameters have been widely used in clinical practice for the assessment of optimal stent procedure. prognostic value of post-stent ffr (ffrpost) have been rarely evaluated in patient treated with 2nd generation des. this multicentre, prospective registry was aimed to evaluate the influence of physiologic parameters on the clinical outcome after 2nd generation des implantation.

patients who diagnosed obstructive coronary artery disease and treated by des with ffr examination would be enrolled, consecutively. ffr measurement would be required at the baseline and at the end of index pci procedure. pci procedure would be performed upon local routine. any available 2nd generation des could be used. informed consent should be obtained and protocol should be approved by each collaborator's institutional review board (irb). web-based electronic-case record form (crf) system will be used for collecting data. all data will be handled and analyzed by blind fashion at independent core lab. patient will be followed-up at each collaborator's hospital at least 2 year after index procedure. any adverse event will be reported and addressed immediately by appropriate medical treatment to protect patient.

Eligibility criteria:
inclusion criteria: * any patient meets eligible criteria who underwent pci with des followed by ffr measurement at the index procedure * patient who provide informed consent exclusion criteria: * culprit vessel of acute coronary syndrome * failed achieving timi 3 flow at the end of pci * left ventricular ejection fraction \<30% * graft vessel * collateral feeder * in-stent stenosis * primary myocardial or valvular heart disease * in patient whose life expectancy less than 2 years * visible thrombus of target vessel segment

Keywords: fractional flow reserve drug eluting stent coronary atherosclerosis
infection control for severe acute respiratory syndrome coronavirus 2

Conditions: Covid19; SARS-CoV Infection; SARS Pneumonia; Coronavirus Infection; Infection

Summary: the investigators aim to develop expert consensus statements on infection control management of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in intensive care units (icu).

the covid-19 pandemic has resulted in a considerable change in the infection control protocols in the hospitals, especially icu. the icu management of these patients requires robust infection control measures in order to prevent cross-transmission of sars-cov-2 (to healthcare workers (hcws) and other patients) and hospital acquired bacterial or fungal infections. the understanding of epidemiological characteristics of sars-cov-2 and pathophysiology of coronavirus disease 2019 (covid-19) along with evidence on transmission of sars-cov-2 in controlled healthcare-setting is still evolving. the mode of transmission of sars-cov-2 is airborne, through droplets or fomites. respiratory interventions performed in these patients in icu, such as non-invasive ventilation, high flow nasal oxygen or tracheal intubation are considered to be aerosol generating procedures and may lead to airborne transmission of sars-cov-2. in the absence of the robust evidence, there are no specific recommendations available on infection control of sars-cov-2 in icu. the objective of this study is to achieve consensus statements on the infection control management of sars-cov-2 in icu. the whole process of this study will be done in the form of three-four rounds of google forms-based delphi surveys. the survey questionnaire, will be prepared by the investigators after systematic search of available literature and concern areas in the infection control of sars-cov-2 in icu. the objective is to achieve consensus statements on the infection control management of sars-cov-2 in icu. the survey questionnaire is divided into five sections: 1.design and engineering 2.health-care workers and visitors 3. personal protective equipment 4. patient and procedures 5. disinfection and sterilisation. the majority of these questionnaire statements are to be rated on likert scale and others have multiple choices. the participating experts comments and feedback will be collected through comment section after each question in round one. all the subsequent surveys will be iterative and the experts can give their opinion in each round using either open text or directly to steering group of investigators.

Eligibility criteria:
inclusion criteria for participants health care professionals involved in the management of covid-19 patients with publications and expertise in infectious disease, infection control, sepsis, respiratory failure or public health. exclusion criteria: * those who do not accept the invitation or not meeting any of the inclusion criteria.

Keywords: infection control intensive care unit sars-cov-2 covid-19
one-year survey of anaphylaxis in outpatient children allergic to peanuts, walnuts/hazelnuts, shellfish

Conditions: Food Allergy

Summary: in italy, few data about anaphylaxis due to peanuts in pediatric age are available, conversely data about walnuts/hazelnuts, shellfish/mollusks anaphylaxis have not yet been collected. children with physician-confirmed food allergy to peanuts, walnuts/hazelnuts and shellfish/mollusks will be recruited from 9 allergy clinics located in the italian territory (bologna, lecce, napoli, palermo, parma, pavia, roma, torino, trento). parent of food allergic children will compile a food allergy questionnaire (questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources). parent of healthy children will compile a control questionnaire (questions about general information on the family, on life and food habits and on indoor environment) the 1-year survey will determine the frequency of anaphylaxis in allergic outpatient children.


Eligibility criteria:
inclusion criteria * cases: 0-14 years old patients with food allergy to peanuts, walnuts/hazelnuts, shellfish/mollusks. * controls: 0-14 years old subjects without allergy to peanuts, walnuts/hazelnuts, shellfish/mollusks. exclusion criteria * patients/subjects in acute phase of disease or with not controlled chronic pathologies; * missing written informed consent by parents

Keywords: children allergy peanuts hazelnuts walnuts mollusks shellfish food
respiratory viral infection in nursing home slovenia

Conditions: Acute Viral Respiratory Tract Diseases

Summary: this study will be conducted in a 208-bed nursing home in maribor. the investigators will observe a group of a 100 nursing-home residents and 50 health care workers- employees in the nursing home- in a six months period.influenza vaccination status will be recorded in all participants at the beginning. at the beginning and at the end of the study the blood samples for vitamin d concentration determination and nasopharyngeal swabs for molecular detection of respiratory viruses will taken in all of the participants. the study will observe number of viral respiratory tract infection in participants and identify the viral etiology of infections during 6 months observational period.nasopharyngeal swab and blood sample will be taken in each of the participant who will suffer an acute respiratory tract infection (upper or lower respiratory tract infection) and viral agents of respiratory tract diseases will be searched for. the investigators will try to detect different viral agents of respiratory tract infection: human rhinoviruses, enteroviruses, influenza a, b, parainfluenza 1-4, respiratory syncytial virus, human coronaviruses, human metapneumovirus, adenoviruses and human bocavirus with newer molecular methods (real-time polymerase chain reaction, real-time reverse transcriptase polymerase chain reaction) in nasopharyngeal swab and in blood sample of the participants. during the study period the investigators will monitor the daily number of visitors (adults, preschool children and pupils) in each nursing home room. the epidemiological aspect of respiratory viral infection will be assessed. our study hypothesis is that lower respiratory tract infections in elderly can be caused by viruses other than influenza. the investigators would like to know if hypovitaminosis d is a risk factor for respiratory tract infections in nursing home residents and employees. the investigators would also like to know if the number of respiratory tract infections in elderly correlates with the number of visitors in nursing home, small children in particular.


Eligibility criteria:
inclusion criteria: * resident of the nursing home or employee ni the nursing home exclusion criteria: * none
treatment of asymptomatic toxocariasis with albendazole in children

Conditions: Toxocariasis

Summary: the purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite toxocara in children. treatment response is defined as a reduction in the number of eosinophils in blood. the study drug will be compared to placebo and randomly assigned in a double blind manner. follow up will be prospective. 50 children (25 per group) will be enrolled in the study.


Eligibility criteria:
inclusion criteria: * pediatric ambulatory patients with asymptomatic toxocariasis * children 2 - 15 years old * absolute eosinophil count \> 1100 / mm3 * normal ophthalmoscopy exclusion criteria: * treatment with a benzimidazole in the previous year * infection by other nematodes (ascaris lumbricoides, strongyloides stercoralis, uncinarias, trichuris trichuria) * symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly, ocular compromise due to toxocara) * concomitant diseases * immunocompromised patients * altered liver or kidney function * pregnancy

Keywords: toxocara pediatrics albendazole eosinophilia parasitology pediatric clinical pharmacology
comparative head lice therapy with dimet 5® vs. hedrin® once

Conditions: Head Lice Infestation; Pediculosis Capitis; Lice

Summary: randomized, investigator-blinded, controlled, multicenter comparative study on the treatment of acute head lice infestation in children with 2 dimeticone preparations with different application times and compositions: dimet 5® (100% dimeticone) versus hedrin® once liquid gel (4% dimeticone + nerolidol) with treatment success assessment via freedom from infestation of live head lice at final examination at v2, i.e. day 19 after first treatment.


Eligibility criteria:
inclusion criteria: * acute head lice infestation * age ≥ 6 months * adequate informed consent for study participation: * age-appropriate informed consent and verbal informed consent from the patient (if capable of both). * written informed consent from the legal guardian(s) (written and verbal). exclusion criteria: * adults (≥ 18 years of age) * known hypersensitivity to any component of the test or comparator product. * scalp lice therapy in the previous 2 weeks (with an appropriate drug or medical device). * severe disease of the scalp or injuries/open wounds on the hairy head * secondary infection in the area of the hairy head * treatment with cotrimoxazole or trimethoprim in the last 4 weeks or new treatment to be initiated now * other relevant reasons, e.g. diseases or dysfunctions, which, in the opinion of the investigator, militate against the inclusion of the patient in the study (including risk factors for severe covid-19 disease in the case of sars-cov-2 infection) * simultaneous participation of another household member in the trial. * previous participation in this trial * participation in another trial within the last 30 days * inability of the legal guardian(s) to understand the study content and instructions. * limited legal capacity of the legal guardian(s) * apparent unreliability or unwillingness to cooperate on the part of the legal guardian(s) * known alcohol, medication or drug dependency of the legal guardian(s) * dependence of the patient or guardian on the sponsor or investigator.
registry of etanercept use in patients with rheumatoid arthritis in clinical practice in taiwan

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in taiwan.


Eligibility criteria:
inclusion criteria: main inclusion criteria: 1) male or female patients aged \> 20 years; 2) patients who have already been selected and approved under the taiwan national health insurance program to receive 24 weeks of etanercept for rheumatoid arthritis. main exclusion criteria: exclusion criteria: none
innovations to prevent relapse among low-income african american smokers

Conditions: Smoking Cessation

Summary: the purpose of this research is to study a relapse prevention program for adult former smokers in northeast ohio. the study will also look at how different people respond to the program. participants asked to take part in this study because they contacted the team for help remaining tobacco-free or otherwise expressed interest in the program. the study includes completing surveys and receiving text messages to help stay tobacco free.

the main objective of this study is to conduct a pilot study to assess the feasibility, acceptability, and initial efficacy/clinical significance of a tobacco relapse prevention intervention designed for low-income african americans. in this study, the team will estimate effect sizes for a culturally specific (cs) relapse prevention intervention compared to standard relapse prevention in a sample of low-income african american smokers and examine predictors of time to smoking relapse. in a community-based clinical trial, adults who recently quit smoking (n=100) will be randomly assigned to one of two experimental conditions: (1) cs relapse prevention or (2) standard relapse prevention. the primary outcome variables collected will include biochemically verified point prevalence abstinence (ppa) at 6-weeks and time to smoking relapse (ttr) over 3-months. this study will test daily hassles, cessation self-efficacy, coping strategies, and adherence to nrt as individual difference factors that may affect response to cs relapse prevention.

Eligibility criteria:
inclusion criteria: * adult smokers recruited from the community by study community navigator and flyers * self-identify as african american * report no tobacco smoking within the past 3-90 days and have a carbon monoxide (co) reading of ≤ 3 ppm * have access to sms texting * meet federal definitions of low-income exclusion criteria: - study team will offer to enroll ineligible smokers in the publicly available smokefreetxt (if applicable) or refer them to the ohio state quitline
safety and efficacy of gs-4774 in combination with tenofovir disoproxil fumarate (tdf) for the treatment of participants with chronic hepatitis b (chb) and who are currently not on treatment

Conditions: Chronic Hepatitis B

Summary: the primary objectives of this study are to evaluate the safety, tolerability, and efficacy of gs-4774 in adults with chb and who are currently not on treatment. participants will be randomized to receive tdf alone or gs-4774 plus tdf for 20 weeks. after week 20, gs-4774 will be discontinued. all participants will continue on tdf and will be followed for an additional 28 weeks. following completion of the 48 week study period, all participants will be eligible for a treatment extension for 96 weeks.


Eligibility criteria:
key inclusion criteria: * must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study * documented evidence of chronic hepatitis b virus (hbv) infection, for example, hepatitis b surface antigen (hbsag) positive for more than 6 months * screening hbv dna ≥ 2000 iu/ml * a negative serum pregnancy test is required for females (unless surgically sterile or \> 2 years post-menopausal) key exclusion criteria: * cirrhosis * inadequate liver function * co-infection with hepatitis c virus (hcv), hiv or hepatitis d virus (hdv) * received antiviral treatment for hbv within 3 months of screening * evidence of hepatocellular carcinoma (eg, as evidenced by recent imaging) * significant cardiovascular, pulmonary, or neurological disease * women who are pregnant or may wish to become pregnant during the course of the study * received solid organ or bone marrow transplant * received prolonged therapy with immunomodulators (eg, corticosteroids) or biologics (eg, monoclonal antibody, interferon) within 3 months of screening * use of investigational agents within 3 months of screening * current alcohol or substance abuse judged by the investigator to potentially interfere with individual's compliance * receipt of immunoglobulin or other blood products within 3 months prior to enrollment * history of demyelinating disease (guillain-barre), bell's palsy, crohn's disease, ulcerative colitis, or autoimmune disease * documented history of yeast allergy * known hypersensitivity to study drugs, metabolites or formulation excipients * malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (basal cell skin cancer, etc). individuals under evaluation for possible malignancy are not eligible note: other protocol defined inclusion/exclusion criteria may apply.
translational neuroscience optimization of glyt1 inhibitor

Conditions: Cognitive Impairments Associated With Schizophrenia

Summary: this is a phase ii, randomized, double-blind, placebo-controlled, cross-over poc study of stable patients with schizophrenia or schizoaffective disorder. the primary objective of this study is to test the efficacy of treatment with one of two does of a glycine transporter inhibitor (glyt1i) combined with cognitive remediation to enhavce cognitive function. subjects will be randomized to one of two doses of the glycine transporter inhibitor (glyt1i) and placebo twice daily in addition to their antipsychotic medication for 2 treatment periods, each lasting a minimum of 5 weeks. treatment periods will be separated by a washout period lasting approximately 3 weeks.


Eligibility criteria:
inclusion criteria: * 1) males or females 21 to 65 years of age (inclusive). * 2) diagnosis of schizophrenia or schizoaffective disorder * 3) able to provide written informed consent. * 4) only cyp2d6 extensive metabolizers. exclusion criteria: * 1) no ongoing acute medical issues * 2) clinically significant ecg abnormality * 3) blood donation within eight weeks of the start of the study * 4) current treatment with clozapine
sms guided training after acute stroke

Conditions: Acute Stroke

Summary: the purpose of this exploratory study is to investigate how a predetermined outdoor walking program (12 weeks) is best delivered to individuals with stroke over 18 years, either by smartphone and the short message service (sms) or video link. furthermore, the aim is to investigate how the study design works in practice and determine the effects of the outdoor walking exercise program in combination with a leg exercise on physical functioning (walking capacity, gait speed, mobility and grip strength).

twenty community-living individuals in uppsala municipality will be included and treated with a cross-over design. ten individuals will initially receive exercise instructions to their smartphones via short message service (sms) for 6 weeks and after that instructions by a video link (6 weeks). another 10 individuals will initially receive instructions by a video link and then switching to management with sms after 6 weeks of training. intervention: participants are supposed to perform an outdoor walking exercise program for 12 weeks. the walks should gradually increase in frequency and intensity, and is expected to start after discharge from the stroke department, after the assessment. the first 2 weeks start with daily walks. the walks will be conducted at a pace that increases the heart rate but still makes it possible to talk. the intensity and frequency of walks will progressively increase performed according to the borg scale: 12-15, ie, moderate to strenuous. participants will walk 5-7 days/week. added to this is a strength exercise, which should be performed in connection with the walk training. methods: questionnaires and medical records used for documentation of age, sex, comorbidity, blood pressure, medications and previous education. assessment of motor function, cognition, level of physical activity are only performed as screening at baseline measurements. objective evaluation of the participants' adherence to the outdoor walking program will be measured with a training diary where the individual documents whether they have followed the training instructions. power analysis is not performed since this is an exploratory study. the investigators will analyze the data using an intention-to -treat. the investigators will also do a 'per-protocol analysis, where only participants who completed the training are included. participants should have participated in at least 50% of the training sessions. all analyzes will be done using spss version 23 (ibm, armonk).

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years 2. verified ischemic cerebral infarction or intracerebral hemorrhage. 3. sufficient walking capacity and motor function 4. able to communicate in swedish 5. signed consent exclusion criteria: are one or more of the following: 1. subarachnoid bleeding 2. insufficient cognition and impaired ability to understand instructions 3. medical problems that make it unsuitable to participate

Keywords: stroke exercise walking mobility